Theme: Pharmaceutical Innovations: much more than just medicine

Pharma Middle East 2017

Pharma Middle East 2017

Scientific Sessions

Conference Series LLC invites all the participants across the globe to attend the 12th Annual Pharma Middle East Congress, September 25-27, 2017 at Dubai, UAE.

Pharma Middle East 2017 is a scientific platform to meet fellow key decision makers all-around the Academic Institutions, Healthcare Institutes, Pharmaceutical, Biotech, CROs supply chain, Logistics practitioners making the congress a perfect platform to share experience, foster collaborations through the research talks & presentations to put forward many thought provoking strategies. It's a perfect stage to brainstorm, discover new ideas, search for new skills and a platform to show your capabilities and discoveries to the world. The conference mainly focuses on current topics like drug extraction, phytochemistry and natural products, drug safety, drug discovery, drug delivery, drug regulatory affairs, role of pharmacist and many more. Conference Series LLC organizes a conference series of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Track 1: Pharmacological Sciences

Pharmacological Sciences is the branch of combination of medicine and biology mainly involving the study of drug action where a drug is a man-made, natural, or endogenous molecule which shows a biochemical and/or physiological effect on the cell, tissue, organ, or organism. It is the study of the interactions that between a living organism and chemicals that affect body functioning either physically or biochemically. Substances having medicinal properties are considered as pharmaceuticals or drugs. sub topics under this session includes Neuropharmacology, Endocrine Pharmacology, Clinical Pharmacology, Ethnopharmacology, Pharmacogenetics, Pharmacogenomics, Posology, Behavioral Pharmacology and many more.

Relevant Conferences:

5th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products, July 24-26, 2017 Melbourne, Australia; International Conference and Exhibition on Pharmaceutical Nanotechnology, July 27-29, 2017 Rome, Italy; 7th Global Experts Meeting on Neuropharmacology, July 31-Aug 02, 2017 Milan, Italy; 9th World Congress on Pharmacology, August 07-09, 2017 Paris, France; 11th Annual Global Pharma Summit, August 17-18, 2017 San Francisco, USA; 6th Annual National Rx Drug Abuse & Heroin Summit, April 17-20, 2017 | Atlanta, United States; National Kidney Foundation (NKF) 2017 Spring Clinical Meetings, April 18-22, 2017 | Orlando, United States; Cardiovascular Medicine 2017: Updates for the Practitioner, April 30 - May 04, 2017 | Boston,  United States; Medical Ethics for Professionals - Pharmacist Edition (May), May 20, 2017 | Atlanta, United States; Pharmacy Ethics and Professionalism (June), June 03-04, 2017 | Irvine, United States., 

Related Societies:

Academy of Managed Care Pharmacy (AMCP), American Association of Colleges of Pharmacy (AACP), American Association of Pharmacy Technicians (AAPT), American Society for Clinical Pharmacology and Therapeutics , American Society of Consultant Pharmacists (ASCP), American Society of PharmacognosyAustrian Association of Hospital Pharmacists.

Track 2: Bio-Pharmaceutical Sciences

Biopharmaceutical Science includes study of the drug discovery and their development, along with their properties, both physical and chemical. It also deals with the biological effects of drugs like onset and duration of action along with their intensity in the body. Biopharmaceutics help in calculating the bioavailability and therapeutic activity of the drugs in the body.

Relevant Conferences:

5th International Pharmacy Conference, April 27-28, 2017 Las Vegas, USA; International Conference and Exhibition on Pharmaceutical Formulations, Aug 28-30, 2017 Brussels, Belgium;  International Conference on Next Generation Nanotechnology, September 18-19, 2017 Jackson Ville, USA; 8th Annual Pharmaceutical Analysis Congress, Sep 25-27, 2017 Vienna, Austria; 10th Pharmacovigilance Congress, Sep 25-27, 2017 Jackson Ville, USA; Understanding Global Healthcare Delivery, June 09-10, 2017 | Boston, United States; Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice 2017, October 12-13, 2017 | Rochester, United States; Smoking Cessation, December 01, 2015 - December 01, 2017 | Miami, United States; 2017 2nd International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2017)--Scopus, EBSCO, April 11_ 13, 2017 Seoul, Korea (south);2017 7th International Conference on Biomedical Engineering and Technology (ICBET 2017), April 24-26, 2017, Kuala Lumpur, Malaysia.

Related Societies:

Austrian Pharmaceutical SocietyCanadian Society for Pharmaceutical SciencesDrug Information AssociationGeorgia Pharmacy AssociationIllinois Pharmacists AssociationInternational Pharmaceutical Federation (FIP).

Track 3: Pharmacognosy and Phytochemistry

Pharmacognosy is the investigation of medications obtained from plant and herbal sources. Most pharmacognostic studies concentrate on plants and medications obtained from plants, different sorts of living beings, different types of microorganisms and also from different marine life forms. This session is mainly dealth with presentations on different branches of Pharmacognosy such as Medical Ethnobotany, Ethnopharmacology, Phytotherapy, Phytochemistry, Phytoconstituents, Zoopharmacognosy, Marine Pharmacognosy and many more.

Relevant Conferences:

International Conference on Biotech Pharmaceuticals, October 23-25, 2017 Paris, France; 10th International Conference on Neuropharmacology and Neuropharmaceuticals, Oct 23-24, 2017 Dubai, UAE; 16th Annual Medicinal & Pharmaceutical Sciences  Congress, October 26-28, 2017 Osaka, Japan; 10th International Conferences on  Immunopharmacology and Immunotoxicology, Nov 20-22, 2017 Melbourne, Australia;17th International Conference and Exhibition on  Nanomedicine  and Nanotechnology in Health Care, July 24-25, 2017 Brisbane, Australia; 2017 8th International Conference on Food Engineering and Biotechnology (ICFEB 2017), April 28-30, 2017 Kuala Lumpur, Malaysia; International Conference on Biomedical Engineering and Systems, June 05- 06, 2017 Rome, Italy; World Congress on Drug Discovery and Development – 2017, September 20-22, 2017 Kolkata, India; 7th Eilat International Educational Course: PHARMACOLOGICALTREATMENT OF EPILEPSY, October 15-20, 2017 Jerusalem, Israel; International Summit on Pharma & Clinical Trials, June 12-13, 2017 syd, New South Wales, Australia.

Related Societies:

 International Pharmaceutical Students' FederationMaryland Pharmacists Association – MphANational Association of Boards of Pharmacy (NABP), National Pharmaceutical AssociationNorth Carolina Association of Pharmacists.

Track 4: Pharmaceutical Chemistry and Medicinal Chemistry

Pharmaceutical chemistry and Medicinal chemistry are Sciences with a combination of chemistry, mainly synthetic organic chemistry and pharmacology. These Sciences are involved with drug design, chemical synthesis and development for pharmaceutical agents market or bio-active molecules. Pharmaceutical Chemistry includes several branches like Biochemistry, Organic Chemistry, Inorganic Chemistry and Medicinal Chemistry. 

Relevant Conferences:

10th International Conference on Emerging Materials and Nanotechnology, July 27-29, 2017 Vancouver, Canada; Global  Pharmaceutical Microbiology  Conference, June 19-20, 2017 London, UK; 14th International Conference on Nanomaterials and Nanotechnology, March 30- 31, 2017 Madrid, Spain; 12th Nanotechnology Products and Summit, November 24-25, 2016 Melbourne, Australia; 3rd World Chemistry Conference, September 11-12, 2017 Dallas, USA; 18th Annual Drug Discovery Summit Conference, June 12-13, 2017 Berlin, Germany; 13th European Congress of Clinical Pharmacology and Therapeutics - EACPT 2017, June 24-27, 2017 Prague, Czech Republic; 9th International Congress on Traditional Asian Medicines (ICTAM IX), August 06-12, 2017 Kiel, Germany; 6th FIP Pharmaceutical Sciences World Congress 2017 Conference, May 21-24, 2017 Stockholm, Sweden; 2nd International Pharmacy Conference, April 27-28, 2017 Las Vegas, Nevada, United States of America.

Related Societies:

Ohio Pharmacists AssociationOklahoma State Board of PharmacyPharmaceutical Research and Manufacturers of America (PhRMA), Pharmaceutical Society of Australia.

Track 5: Nanotechnology

Nanotechnology is being used in the pharmaceutical field for different reasons. The main reason is to improve drug solubility and delivery to various sites for action. Nanotechnology is also used to develop new and improved therapeutic devices. Therapeutics are improved through both the consistent drug delivery, drug targeting and bioavailability of existing medicinal moities, including the discovery of completely new substances and nanomaterials, which brings out different added advantages over classical drug delivery systems, including the targeted delivery to effected sites only, and the improved adsorption, distribution and duration of medication in the body.

Relevant Conferences:

2nd International Conference on Pharmaceutical Chemistry, October 02-04, 2017 Barcelona, Spain; 2nd International Conference on Applied Chemistry, October 16-17, 2017 Toronto, Canada; 2nd World Biotechnology Congress, December 04-06, 2017 Sao Paulo, Brazil; Global Pharmaceutical Microbiology Conference, June 19-20, 2017 London, UK; International Conference on Pharmaceutical and Biomedical Engineering, June 12-13, 2017 Taipei, Taiwan; Clinical Trials Conference 2017, April 10-12, 2017 Washington D.C., District of Columbia, United States of America; 2017 2nd International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2017)--Scopus, EBSCO, April 11-13, 2017 Seoul, Korea (south); International Interdisciplinary Conference on Science, Technology, Engineering, Management, Pharmacy and Humanities, April 22-23, 2017 Singapore; International Congress and Exhibition on Pharmacy, April 03-05, 2017 Dubai, United Arab Emirates; III International Conference on Clinical Sciences and Drug Discovery, November 06-08, 2017 Washington DC, United States of America.

Related Societies:

Pharmaceutical Society of KoreaRoyal Pharmaceutical Society of Great BritainSouth Carolina Pharmacy AssociationUtah Pharmaceutical AssociationTennessee Pharmacists Association.

Track 6: Drugs and Regulations

Drugs are not simple consumers’ products. In most cases, consumers are not in a position to make any decisions regarding the usage of drugs, which drugs to use, how to use them and to weigh exact benefits without knowing the risk as no medicine is completely safe. Experts’ advice from either prescribers or dispensers is needed in making decisions about their usage. The session include presentations on  Regulations and organizations, implementation of pharmacogenetics in USA,  Clinical Pharmacy Services, Health care management, Drug safety regulations, Drug rediscovery, multiple drug use, Good governance in pharmacy and so on.......

Relevant Conferences:

5th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products, July 24-26, 2017 Melbourne, Australia; International Conference and Exhibition on Pharmaceutical Nanotechnology, July 27-29, 2017 Rome, Italy; 7th Global Experts Meeting on Neuropharmacology, July 31-Aug 02, 2017 Milan, Italy; 9th World Congress on Pharmacology, August 07-09, 2017 Paris, France; 11th Annual Global Pharma Summit, August 17-18, 2017 San Francisco, USA; 6th Annual National Rx Drug Abuse & Heroin Summit, April 17-20, 2017 | Atlanta, United States; National Kidney Foundation (NKF) 2017 Spring Clinical Meetings, April 18-22, 2017 | Orlando, United States; Cardiovascular Medicine 2017: Updates for the Practitioner, April 30 - May 04, 2017 | Boston,  United States; Medical Ethics for Professionals - Pharmacist Edition (May), May 20, 2017 | Atlanta, United States; Pharmacy Ethics and Professionalism (June), June 03-04, 2017 | Irvine, United States.

Related Societies:

American Society for Clinical Pharmacology and Therapeutics , American Society of Consultant Pharmacists (ASCP), American Society of PharmacognosyAustrian Association of Hospital Pharmacists , Austrian Pharmaceutical Society.

Track 7: Industrial Pharmacy and Pharmacy Practice

By definition Industrial Pharmacy is a discipline which includes manufacturing, development, marketing and distribution of drug products including quality assurance of these activities. This broad research area relates to different functions in pharmaceutical industry and having contact areas with engineering and economics.

Pharmacy practice is the discipline of pharmacy which involves developing the professional roles of pharmacists. Disease-state management, Clinical interventions (refusal to dispense a drug, recommendation to change and/or add a drug to a patient's pharmacotherapy, dosage adjustments, Professional development, Pharmaceutical care, Extemporaneous pharmaceutical compounding, Patient care, Drug abuse prevention, Prevention of drug interactions, including drug-drug interactions or drug-food interactions, Prevention (or minimization) of adverse events, Incompatibility, Drug discovery and evaluation, Community Pharmacy etc.,

Relevant Conferences:

5th International Pharmacy Conference, April 27-28, 2017 Las Vegas, USA; International Conference and Exhibition on Pharmaceutical Formulations, Aug 28-30, 2017 Brussels, Belgium;  International Conference on Next Generation Nanotechnology, September 18-19, 2017 Jackson Ville, USA; 8th Annual Pharmaceutical Analysis Congress, Sep 25-27, 2017 Vienna, Austria; 10th Pharmacovigilance Congress, Sep 25-27, 2017 Jackson Ville, USA; Understanding Global Healthcare Delivery, June 09-10, 2017 | Boston, United States; Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice 2017, October 12-13, 2017 | Rochester, United States; Smoking Cessation, December 01, 2015 - December 01, 2017 | Miami, United States; 2017 2nd International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2017)--Scopus, EBSCO, April 11_ 13, 2017 Seoul, Korea (south);2017 7th International Conference on Biomedical Engineering and Technology (ICBET 2017), April 24-26, 2017, Kuala Lumpur, Malaysia.

Related Societies:

Drug Information AssociationGeorgia Pharmacy AssociationIllinois Pharmacists AssociationInternational Pharmaceutical Federation (FIP), International Pharmaceutical Students' FederationMaryland Pharmacists Association – MphA.

Track 8: Genetics, Genetic Engineering and Biomedical Engineering

Genetics is the Science of genes, genetic variation and heredity living beings. It is generally considered as a field of biology, but it is mostly an Interdisciplinary Science which involves with many of the life sciences and is potentially related with the study of information systems. Biomedical Engineering is the application of Engineering principles and design concepts to drugs and biology for an emerging healthcare Industries like diagnostics and therapeutics. This Science has filled the gap between engineering and medicine: It adds the advantages of the problem solving skills and design of engineering with medical and biological sciences to improve health care treatment.

Relevant Conferences:

International Conference on Biotech Pharmaceuticals, October 23-25, 2017 Paris, France; 10th International Conference on Neuropharmacology and Neuropharmaceuticals, Oct 23-24, 2017 Dubai, UAE; 16th Annual Medicinal & Pharmaceutical Sciences  Congress, October 26-28, 2017 Osaka, Japan; 10th International Conferences on Immunopharmacology and Immunotoxicology, Nov 20-22, 2017 Melbourne, Australia;17th International Conference and Exhibition on Nanomedicine and Nanotechnology in Health Care, July 24-25, 2017 Brisbane, Australia; 2017 8th International Conference on Food Engineering and Biotechnology (ICFEB 2017), April 28-30, 2017 Kuala Lumpur, Malaysia; International Conference on Biomedical Engineering and Systems, June 05- 06, 2017 Rome, Italy; World Congress on Drug Discovery and Development – 2017, September 20-22, 2017 Kolkata, India; 7th Eilat International Educational Course: PHARMACOLOGICALTREATMENT OF EPILEPSY, October 15-20, 2017 Jerusalem, Israel; International Summit on Pharma & Clinical Trials, June 12-13, 2017 syd, New South Wales, Australia.

Related Societies:

National Association of Boards of Pharmacy (NABP), National Pharmaceutical AssociationNorth Carolina Association of PharmacistsOhio Pharmacists AssociationOklahoma State Board of Pharmacy.

Track 9: Ethics in Pharmacy

The Science of pharmacy practice develops pharmacists as health professionals with the knowledge, skills and helps in building Pharmacists as responsible citizens for drug utilization and their management, to optimize the health outcomes though medicines. Pharmacy practice deals with the technical aspects of applied pharmacy services, dispensing of drugs and their supply management with patient-centred care through counseling, providing correct drug information and monitoring drug therapy in person.

Relevant Conferences:

10th International Conference on Emerging Materials and Nanotechnology, July 27-29, 2017 Vancouver, Canada; Global  Pharmaceutical Microbiology  Conference, June 19-20, 2017 London, UK; 14th International Conference on Nanomaterials and Nanotechnology, March 30- 31, 2017 Madrid, Spain; 12th Nanotechnology Products and Summit, November 24-25, 2016 Melbourne, Australia; 3rd World Chemistry Conference, September 11-12, 2017 Dallas, USA; 18th Annual Drug Discovery Summit Conference, June 12-13, 2017 Berlin, Germany; 13th European Congress of Clinical Pharmacology and Therapeutics - EACPT 2017, June 24-27, 2017 Prague, Czech Republic; 9th International Congress on Traditional Asian Medicines (ICTAM IX), August 06-12, 2017 Kiel, Germany; 6th FIP Pharmaceutical Sciences World Congress 2017 Conference, May 21-24, 2017 Stockholm, Sweden; 2nd International Pharmacy Conference, April 27-28, 2017 Las Vegas, Nevada, United States of America.

Related Societies:

Pharmaceutical Research and Manufacturers of America (PhRMA), Pharmaceutical Society of AustraliaPharmaceutical Society of KoreaRoyal Pharmaceutical Society of Great Britain.

Track 10: Preformulation Studies and Techniques

Preformulation studies are important elements to be considered during the process of drug development research to support development of formulations at different phases of clinical trials. As from the word preformulation the activities that are done before formulation development are called as preformulation studies. It gives the scientific basis for formulation development. This session is concentrated on topics like solubility, dissociation constant, salt formation, partition or distribution coefficient, pH, polymorphism, solubility profile and dissolution kinetics etc.,

Relevant Conferences:

2nd International Conference on Pharmaceutical Chemistry, October 02-04, 2017 Barcelona, Spain; 2nd International Conference on Applied Chemistry, October 16-17, 2017 Toronto, Canada; 2nd World Biotechnology Congress, December 04-06, 2017 Sao Paulo, Brazil; Global Pharmaceutical Microbiology Conference, June 19-20, 2017 London, UK; International Conference on Pharmaceutical and Biomedical Engineering, June 12-13, 2017 Taipei, Taiwan; Clinical Trials Conference 2017, April 10-12, 2017 Washington D.C., District of Columbia, United States of America; 2017 2nd International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2017)--Scopus, EBSCO, April 11-13, 2017 Seoul, Korea (south); International Interdisciplinary Conference on Science, Technology, Engineering, Management, Pharmacy and Humanities, April 22-23, 2017 Singapore; International Congress and Exhibition on Pharmacy, April 03-05, 2017 Dubai, United Arab Emirates; III International Conference on Clinical Sciences and Drug Discovery, November 06-08, 2017 Washington DC, United States of America.

Related Societies:

South Carolina Pharmacy AssociationUtah Pharmaceutical AssociationTennessee Pharmacists AssociationAcademy of Managed Care Pharmacy (AMCP), American Association of Colleges of Pharmacy (AACP), American Association of Pharmacy Technicians (AAPT).

Track 11: Clinical Pharmacy and Pharmacotherapeutics

Clinical pharmacy is the discipline of Pharmacy where pharmacists are meant to provide patient care which helps in optimizing the use of drugs and improves health, wellness, and prevents diseases. This session is dealt with topics like basic components of clinical pharmacy practice Prescribing drugs, Reviewing drug use, Administering drugs, Counseling, Documenting professional services, Consulting, Preventing Medication Errors etc.,

Relevant Conferences:

5th International Conference and Exhibition on Pharmacognosy, Phytochemistry & Natural Products, July 24-26, 2017 Melbourne, Australia; International Conference and Exhibition on Pharmaceutical Nanotechnology, July 27-29, 2017 Rome, Italy; 7th Global Experts Meeting on Neuropharmacology, July 31-Aug 02, 2017 Milan, Italy; 9th World Congress on Pharmacology, August 07-09, 2017 Paris, France; 11th Annual Global Pharma Summit, August 17-18, 2017 San Francisco, USA; 6th Annual National Rx Drug Abuse & Heroin Summit, April 17-20, 2017 | Atlanta, United States; National Kidney Foundation (NKF) 2017 Spring Clinical Meetings, April 18-22, 2017 | Orlando, United States; Cardiovascular Medicine 2017: Updates for the Practitioner, April 30 - May 04, 2017 | Boston,  United States; Medical Ethics for Professionals - Pharmacist Edition (May), May 20, 2017 | Atlanta, United States; Pharmacy Ethics and Professionalism (June), June 03-04, 2017 | Irvine, United States.

Related Societies:

American Society for Clinical Pharmacology and Therapeutics , American Society of Consultant Pharmacists (ASCP), American Society of PharmacognosyAustrian Association of Hospital Pharmacists , Austrian Pharmaceutical SocietyCanadian Society for Pharmaceutical Sciences.

Track 12: Green Chemistry in Pharmaceutical Industry

Green chemistry, also called sustainable chemistry, is a philosophy of chemical research and engineering that encourages the design of products and processes that minimize the use and generation of hazardous substances. As a chemical philosophy, green chemistry applies to organic chemistry, inorganic chemistry, biochemistry, analytical chemistry, physical chemistry and even chemical engineering.

Relevant Conferences:

5th International Pharmacy Conference, April 27-28, 2017 Las Vegas, USA; International Conference and Exhibition on Pharmaceutical Formulations, Aug 28-30, 2017 Brussels, Belgium;  International Conference on Next Generation Nanotechnology, September 18-19, 2017 Jackson Ville, USA; 8th Annual Pharmaceutical Analysis Congress, Sep 25-27, 2017 Vienna, Austria; 10th Pharmacovigilance Congress, Sep 25-27, 2017 Jackson Ville, USA; Understanding Global Healthcare Delivery, June 09-10, 2017 | Boston, United States; Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice 2017, October 12-13, 2017 | Rochester, United States; Smoking Cessation, December 01, 2015 - December 01, 2017 | Miami, United States; 2017 2nd International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2017)--Scopus, EBSCO, April 11_ 13, 2017 Seoul, Korea (south);2017 7th International Conference on Biomedical Engineering and Technology (ICBET 2017), April 24-26, 2017, Kuala Lumpur, Malaysia.

Related Societies:

Drug Information AssociationGeorgia Pharmacy AssociationIllinois Pharmacists AssociationInternational Pharmaceutical Federation (FIP), International Pharmaceutical Students' FederationMaryland Pharmacists Association – MphA.

Track 13: Pharmaceutical Microbiology and Biotechnology

Pharmaceutical Microbiology is one of the applied branches of Microbiology. It is the study of microorganisms related with the manufacture of pharmaceuticals like minimizing the microorganisms growth in a processed environment, removing microorganisms and their by-products like endotoxin and exotoxin from water and other materials, and ensuring the finished pharmaceutical product sterility. This session includes discussions on aspects of pharmaceutical microbiology including the research and manufacturing of anti-infective agents, the use of microorganisms to find mutagenic and carcinogenic activity in drugs, and the use of microorganisms in pharmaceutical products manufacturing like insulin and human growth hormone.

Relevant Conferences:

International Conference on Biotech Pharmaceuticals, October 23-25, 2017 Paris, France; 10th International Conference on Neuropharmacology and Neuropharmaceuticals, Oct 23-24, 2017 Dubai, UAE; 16th Annual Medicinal & Pharmaceutical Sciences  Congress, October 26-28, 2017 Osaka, Japan; 10th International Conferences on Immunopharmacology and Immunotoxicology, Nov 20-22, 2017 Melbourne, Australia;17th International Conference and Exhibition on Nanomedicine and Nanotechnology in Health Care, July 24-25, 2017 Brisbane, Australia; 2017 8th International Conference on Food Engineering and Biotechnology (ICFEB 2017), April 28-30, 2017 Kuala Lumpur, Malaysia; International Conference on Biomedical Engineering and Systems, June 05- 06, 2017 Rome, Italy; World Congress on Drug Discovery and Development – 2017, September 20-22, 2017 Kolkata, India; 7th Eilat International Educational Course: PHARMACOLOGICALTREATMENT OF EPILEPSY, October 15-20, 2017 Jerusalem, Israel; International Summit on Pharma & Clinical Trials, June 12-13, 2017 syd, New South Wales, Australia.

Related Societies:

National Association of Boards of Pharmacy (NABP), National Pharmaceutical AssociationNorth Carolina Association of PharmacistsOhio Pharmacists AssociationOklahoma State Board of PharmacyPharmaceutical Research and Manufacturers of America (PhRMA).

Track 14: Pharmaceutical Business and Marketing

Marketing of Pharmaceuticals is also called medico-marketing or pharma marketing in most countries, is the business of advertising or promoting the sales of pharmaceuticals or medicines. Many countries have measures in their respective places with limits for advertising by pharmaceutical companies.

Relevant Conferences:

10th International Conference on Emerging Materials and Nanotechnology, July 27-29, 2017 Vancouver, Canada; Global  Pharmaceutical Microbiology  Conference, June 19-20, 2017 London, UK; 14th International Conference on Nanomaterials and Nanotechnology, March 30- 31, 2017 Madrid, Spain; 12th Nanotechnology Products and Summit, November 24-25, 2016 Melbourne, Australia; 3rd World Chemistry Conference, September 11-12, 2017 Dallas, USA; 18th Annual Drug Discovery Summit Conference, June 12-13, 2017 Berlin, Germany; 13th European Congress of Clinical Pharmacology and Therapeutics - EACPT 2017, June 24-27, 2017 Prague, Czech Republic; 9th International Congress on Traditional Asian Medicines (ICTAM IX), August 06-12, 2017 Kiel, Germany; 6th FIP Pharmaceutical Sciences World Congress 2017 Conference, May 21-24, 2017 Stockholm, Sweden; 2nd International Pharmacy Conference, April 27-28, 2017 Las Vegas, Nevada, United States of America

Related Societies:

Pharmaceutical Society of AustraliaPharmaceutical Society of KoreaRoyal Pharmaceutical Society of Great BritainSouth Carolina Pharmacy AssociationUtah Pharmaceutical AssociationTennessee Pharmacists Association.

Track 15: Entrepreneurs Investment Meet

Pharma Middle East 2016 is a platform that targets to connect Entrepreneurs, decision makers and the Investors worldwide. It is intended to create and facilitate the most optimized and viable meeting place for involving people in International business discussions, execution and evaluation of promising business ideas. An investor could be able to find out a lot of potential investment opportunities worldwide, which provide good return on their investments. This would be an ideal place and great opportunity for entrepreneurs to reach out suitable investors and partners to start or expand their business. Hence this is a perfect place to connect Business Owners, Entrepreneurs, Established Corporates and Early Stage Companies with National or International Investors, Corporate Investors and Potential Business Partners.

Relevant Conferences:

2nd International Conference on Pharmaceutical Chemistry, October 02-04, 2017 Barcelona, Spain; 2nd International Conference on Applied Chemistry, October 16-17, 2017 Toronto, Canada; 2nd World Biotechnology Congress, December 04-06, 2017 Sao Paulo, Brazil; Global Pharmaceutical Microbiology Conference, June 19-20, 2017 London, UK; International Conference on Pharmaceutical and Biomedical Engineering, June 12-13, 2017 Taipei, Taiwan; Clinical Trials Conference 2017, April 10-12, 2017 Washington D.C., District of Columbia, United States of America; 2017 2nd International Conference on Pharmacy and Pharmaceutical Science (ICPPS 2017)--Scopus, EBSCO, April 11-13, 2017 Seoul, Korea (south); International Interdisciplinary Conference on Science, Technology, Engineering, Management, Pharmacy and Humanities, April 22-23, 2017 Singapore; International Congress and Exhibition on Pharmacy, April 03-05, 2017 Dubai, United Arab Emirates; III International Conference on Clinical Sciences and Drug Discovery, November 06-08, 2017 Washington DC, United States of America. 

Related Societies:

Austrian Pharmaceutical SocietyCanadian Society for Pharmaceutical SciencesDrug Information AssociationGeorgia Pharmacy AssociationIllinois Pharmacists AssociationInternational Pharmaceutical Federation (FIP).





About Conference

With the success of Pharma Middle East 2016, Conference Series LLC proudly announces and invites all the participants across the globe to attend the "12th Annual Pharma Middle East Congress” slated on  Sep 25-27, 2017 at Dubai, UAE.

Pharma Middle East 2017 is a scientific platform to meet fellow key decision makers all-around the Academic Institutions, Healthcare Institutes, Pharmaceutical, Biotech, CROs supply chain, Logistics practitioners making the congress a perfect platform to share experience, foster collaborations through the research talks & presentations to put forward many thought provoking strategies. It's a perfect stage to brainstorm, discover new ideas, search for new skills and a platform to show your capabilities and discoveries to the world. The conference mainly focuses on current topics like drug extraction, phytochemistry and natural products, drug safety, drug discovery, drug delivery, drug regulatory affairs, role of pharmacist and many more.

Conference Series LLC organizes a conference series of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Top Reasons to Attend

  • A unique opportunity to discuss issues of importance and relevance to advancing pharmacy practice through continuous professional development.
  • The conference is of interest to all those in the Continuing Education/Professional Development experience, including pharmacists, developers, sponsors, faculty, regulators, government, professional associations, pharmaceutical industry, communication companies, and allied health care providers and organizations from around the world.
  • Meet with key decision makers in the pharmaceutical industry worldwide and learn about the latest innovations, technologies, trends and developments in pharmaceutical industry.
  • Network and gain access to one of the world's fastest growing pharmaceutical markets.
  • A momentum is growing world-wide that recognizes the integral role of continuing professional development in Pharmaceutical Industry, and the value of sharing experiences and knowledge in an international, collegial forum.
  • The conference facilitates participant access to high quality educational programs, internationally significant research and development, and world-renowned leaders in the Pharmaceutical field.
  • This is the only event featuring renowned speakers and delegates and expertise on the topics you care about most!

Target Audience

  • Professors, Associate Professors, Asst Professors
  • PhD Scholars
  • Graduates and Post Graduates
  • Directors, CEO’s of Organizations
  • Association, Association presidents and professionals
  • Noble laureates in Health Care and Medicine
  • Bio instruments Professionals
  • Research Institutes and members
  • Supply Chain companies
  • Manufacturing Companies
  • Training Institutes
  • Business Entrepreneurs




Market Analysis

The Pharma Industry is responsible for the development, production and marketing of medications. According to IMS Health Consulting, an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the global pharmaceutical market is expected to reach $1.1 trillion by 2015 and will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. The global demographic, epidemiological and economic changes are transforming the pharmaceutical market. The world population is growing rapidly and is projected to rise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals. The global pharmaceuticals market is worth US$300 billion a year, a figure expected to rise to US$400 billion within three years. Economically, the Middle East (ME) is well positioned to be the one of next growth engine of global pharmaceutical business: several countries in the region enjoy robust economic growth and the highest cash reserves per capita in the world. The pharmaceutical Industry is consequently flourishing as the expanding middle class demands better care, and government healthcare spending continues to grow. The pharmaceutical market in the Middle East is likely to grow by between ten and 15 percent annually over the next three years, outstripping more mature markets, forecasts a report from URCH Publishing. The Middle East pharma markets are showing consistent growth over the last years in particular in the area of specialized medication. The market for pharmaceutical products is still expected to grow in many countries across the region.

  • The Middle East pharma market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn by the end of 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn by the end of 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
  • General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
  • The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007.

Market of Spending on medicines

Past spending growth offers few clues to the level of growth to expect through 2015 – Unprecedented dynamics are at play — including historically high levels of patent expiry, rapid expansion of demand for medicines in the world's fastest growing economies, fewer new medicines reaching patients, and more moderate uptake of those that do become available – These dynamics are driving rapid shifts in the mix of spending between branded products and generics; and between spending in the major developed countries and those 17 high growth emerging countries referred to as 'pharmerging‘.

  • Spending on medicines which was estimated at $856bn in 2010, is expected to reach nearly $1,100bn in 2015, reflecting a slowing growth rate of 36% over the five year period compared to 6.2 % annual growth over the past five years
  • A distinct shift is also expected in the market shares across the globe, with the US and Europe share of global spending declining
  • Meanwhile, 17 high growth emerging markets (pharmerging) including China, India, Brazil, Russia and Mexico will contribute 28 per cent of total spending by 2015, up from only 12 per cent in 2005

Global Pharma Market Growth

According to IMS Health Consulting, an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the global pharmaceutical market is expected to reach $1.1 trillion by 2015 and will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. The global demographic, epidemiological and economic changes are transforming the pharmaceutical market. The world population is growing rapidly and is projected to rise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals.

The ageing process also affects the demand. By 2020 about 9.4% of the world population (719.4 million people) will be 65 or above, compared with 7.3% (477.4 million) in 2005 (UN, 2013). Clinical advances reinforce this trend. The improvements of the past few decades have already converted some previously terminal illnesses into chronic conditions, thus increasing long-term demand for therapies to manage these diseases. Older people consume more medicines than younger people: four in five of those aged over 75 take at least one prescription product, while 36% take four or more. Therefore, the population age structure makes it possible to forecast an increase in the demand for medicines in this age group. Many producers of original medicines will have their patents expire very shortly. This “patent cliff” and the mass production of generics will cause a significant reduction in prices as a result of which the income of the pharmaceutical market will decrease by $148 billion between 2012 and 2018.

Spending on medicines will reach nearly $1,100Bn in 2015, reflecting a slowing growth rate of 3-6% over the five year period compared to 6.2% annual growth over the past five years. Absolute global spending growth is expected to be $210-240Bn, compared to $251Bn since m2005.The U.S. share of global spending will decline from 41% in 2005 to 31% in 2015, while the share of spending from the top 5 European countries will decline from 20% to 13% over the same period. Meanwhile, 17 high growth emerging markets led by China, will contribute 28% of total spending by 2015, up from only 12% in 2005.The next five years will also see an accelerating shift in spending toward generics, rising to 39% of spending in 2015, up from 20% in 2005.

• Growth in the next five years will slow to3-6% CAGR compared to 6.2% over the past five years.

• Spending on medicines globally is expected to exceed $1 trillion dollars in2014 and to reach nearly $1,100Bn by 2015.

• Absolute growth is expected to be $210-240Bn compared to $251Bn in the prior five years.

• Removing the effect of exchange rate fluctuations, growth will be $230-250Bn on a constant dollar basis, compared to $228Bn in the previous five years.

Middle East Pharma Market Growth

The pharmaceutical market in the Middle East is likely to grow by between ten and 15 percent annually over the next three years, outstripping more mature markets, forecasts a report from URCH Publishing.

Major Pharmaceutical Markets of the Middle East (2nd Ed): An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE, says that massive growth is being forecast for the pharmaceutical and biotechnology markets of Middle Eastern states, driven by moves to liberalise national economies, the introduction of mass health insurance and the determination of the region's governments to become self-sufficient in pharmaceuticals production.

All these factors are leading to huge investments taking place in both the private and public health sectors, with major benefits to the pharmaceutical industry.

The population of the Middle East now exceeds 370 million and is expected to reach over 520 million by 2030. The growing population, dominated mainly by the expatriate community in most of the Gulf Corporation Council (GCC) countries, has given rise to a rapidly growing market for healthcare and its associated industries, which is estimated at $75bn in the Middle East alone.

The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. The market dynamics are further shaped by the presence of several leading suppliers of branded generics and APIs (active pharmaceutical ingredients) such as Teva, Hikma, Ibrahim, etc. Although, Middle East countries were a late entrant to the biotech sector, countries like Turkey, Saudi Arabia, UAE and Israel has made a dramatic progress in recent years, which was mainly due to several government initiatives. Moreover, several public-private partnerships also boosted the growth of pharmaceutical sector in the Middle East region.

Key findings

  • The Middle East pharmaceutical market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn by the end of 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn by the end of 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
  • General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
  • The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007.
  • The Middle East represents a diverse mix of markets, with Jordan the largest Arab pharmaceutical exporter in the region and Lebanon almost entirely dependent on imports.
  • With the exceptions of Egypt and Israel, every country in the region is heavily dependent on imports.
  • According to the Jordanian Association of Pharmaceutical Manufacturers, 81 percent of its production is exported, 90 percent of which goes to other countries in the region.
  • Egypt is the largest market, followed by Saudi Arabia.
  • Other significant markets include Jordan, Lebanon, and the United Arab Emirates.
  • The total regional market is valued at over $12 billion and is expected to grow 10 to 15 percent annually, according to various estimates.
  • Smaller markets include countries such as Kuwait, estimated to be worth $365 million, and Oman, valued at $124 million.
  • Both rely largely on imported generics and branded drugs.
  • Israel spends 0.8 percent of GDP on healthcare, and local generics giant Teva Pharmaceutical Industries dominates its generics market.

Importance and scope of Pharma Industry

The pharmaceutical industry represents one of the most dynamic and demanding industries in the world. As health care continues to grow and account for a significant portion of the economy in the United States and throughout the world, the importance of the pharmaceutical and health care industry increases.

Over the years pharmacy has grown in the form of pharmaceuticals sciences through research and development processes. It is related to product as well as to services.

The various drugs 

 

Discovered and developed are its products and the healthcare it provides comes under the category of services

Pharmacy involves all the stages that are associated with the drugs i.e. discovery, development, action, safety, formulation, use, quality control, packaging, storage, marketing, etc. This profession has a large socio-economic relevance to the Indian economy. In India this sector is among the future economy drivers. It is committed to deliver high quality drugs and formulations at an affordable price, so that majority of people can afford them.

This profession has a large socio-economic relevance to the Indian economy. In India this sector is among the future economy drivers. It is committed to deliver high quality drugs and formulations at an affordable price, so that majority of people can afford them. The transformation of the sector from conventional pharmacy to drug experts, which is both desired and necessary to reach the global standards, has already made commendable progress

Liberalization, privatization and globalization (LPG) have helped the Indian pharmaceutical companies to achieve international recognition. It's remarkable to note that today several Indian pharma companies are approved by US FDA and are listed at NASDAQ.

 

The multibillion-dollar pharma industry grows mainly through knowledge wealth creation. This sector has transformed a lot over the years. The big pharma companies that were there about 15-20 years back are not in picture these days. 

 

 

The Pharma Industry is responsible for the development, production and marketing of medications. According to IMS Health Consulting, an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the global pharmaceutical market is expected to reach $1.1 trillion by 2015 and will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. The global demographic, epidemiological and economic changes are transforming the pharmaceutical market. The world population is growing rapidly and is projected to rise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals. The global pharmaceuticals market is worth US$300 billion a year, a figure expected to rise to US$400 billion within three years. Economically, the Middle East (ME) is well positioned to be the one of next growth engine of global pharmaceutical business: several countries in the region enjoy robust economic growth and the highest cash reserves per capita in the world. The pharmaceutical Industry is consequently flourishing as the expanding middle class demands better care, and government healthcare spending continues to grow. The pharmaceutical market in the Middle East is likely to grow by between ten and 15 percent annually over the next three years, outstripping more mature markets, forecasts a report from URCH Publishing. The Middle East pharma markets are showing consistent growth over the last years in particular in the area of specialized medication. The market for pharmaceutical products is still expected to grow in many countries across the region.

  • The Middle East pharma market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn by the end of 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn by the end of 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
  • General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
  • The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007

 

·         Market of Spending on medicines

·         Past spending growth offers few clues to the level of growth to expect through 2015 – Unprecedented dynamics are at play — including historically high levels of patent expiry, rapid expansion of demand for medicines in the world's fastest growing economies, fewer new medicines reaching patients, and more moderate uptake of those that do become available – These dynamics are driving rapid shifts in the mix of spending between branded products and generics; and between spending in the major developed countries and those 17 high growth emerging countries referred to as 'pharmerging‘.

  • Spending on medicines which was estimated at $856bn in 2010, is expected to reach nearly $1,100bn in 2015, reflecting a slowing growth rate of 36% over the five year period compared to 6.2 % annual growth over the past five years
  • A distinct shift is also expected in the market shares across the globe, with the US and Europe share of global spending declining
  • Meanwhile, 17 high growth emerging markets (pharmerging) including China, India, Brazil, Russia and Mexico will contribute 28 per cent of total spending by 2015, up from only 12 per cent in 2005

Global Pharma Market Growth

According to IMS Health Consulting, an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the global pharmaceutical market is expected to reach $1.1 trillion by 2015 and will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. The global demographic, epidemiological and economic changes are transforming the pharmaceutical market. The world population is growing rapidly and is projected to rise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals.

The ageing process also affects the demand. By 2020 about 9.4% of the world population (719.4 million people) will be 65 or above, compared with 7.3% (477.4 million) in 2005 (UN, 2013). Clinical advances reinforce this trend. The improvements of the past few decades have already converted some previously terminal illnesses into chronic conditions, thus increasing long-term demand for therapies to manage these diseases. Older people consume more medicines than younger people: four in five of those aged over 75 take at least one prescription product, while 36% take four or more. Therefore, the population age structure makes it possible to forecast an increase in the demand for medicines in this age group. Many producers of original medicines will have their patents expire very shortly. This “patent cliff” and the mass production of generics will cause a significant reduction in prices as a result of which the income of the pharmaceutical market will decrease by $148 billion between 2012 and 2018.

Spending on medicines will reach nearly $1,100Bn in 2015, reflecting a slowing growth rate of 3-6% over the five year period compared to 6.2% annual growth over the past five years. Absolute global spending growth is expected to be $210-240Bn, compared to $251Bn since m2005.The U.S. share of global spending will decline from 41% in 2005 to 31% in 2015, while the share of spending from the top 5 European countries will decline from 20% to 13% over the same period. Meanwhile, 17 high growth emerging markets led by China, will contribute 28% of total spending by 2015, up from only 12% in 2005.The next five years will also see an accelerating shift in spending toward generics, rising to 39% of spending in 2015, up from 20% in 2005.

• Growth in the next five years will slow to3-6% CAGR compared to 6.2% over the past five years.

• Spending on medicines globally is expected to exceed $1 trillion dollars in2014 and to reach nearly $1,100Bn by 2015.

• Absolute growth is expected to be $210-240Bn compared to $251Bn in the prior five years.

• Removing the effect of exchange rate fluctuations, growth will be $230-250Bn on a constant dollar basis, compared to $228Bn in the previous five years.

Middle East Pharma Market Growth

The pharmaceutical market in the Middle East is likely to grow by between ten and 15 percent annually over the next three years, outstripping more mature markets, forecasts a report from URCH Publishing.

Major Pharmaceutical Markets of the Middle East (2nd Ed): An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE, says that massive growth is being forecast for the pharmaceutical and biotechnology markets of Middle Eastern states, driven by moves to liberalise national economies, the introduction of mass health insurance and the determination of the region's governments to become self-sufficient in pharmaceuticals production.

All these factors are leading to huge investments taking place in both the private and public health sectors, with major benefits to the pharmaceutical industry.

The population of the Middle East now exceeds 370 million and is expected to reach over 520 million by 2030. The growing population, dominated mainly by the expatriate community in most of the Gulf Corporation Council (GCC) countries, has given rise to a rapidly growing market for healthcare and its associated industries, which is estimated at $75bn in the Middle East alone.

The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. The market dynamics are further shaped by the presence of several leading suppliers of branded generics and APIs (active pharmaceutical ingredients) such as Teva, Hikma, Ibrahim, etc. Although, Middle East countries were a late entrant to the biotech sector, countries like Turkey, Saudi Arabia, UAE and Israel has made a dramatic progress in recent years, which was mainly due to several government initiatives. Moreover, several public-private partnerships also boosted the growth of pharmaceutical sector in the Middle East region.

Key findings

  • The Middle East pharmaceutical market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn by the end of 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn by the end of 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
  • General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
  • The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007.
  • The Middle East represents a diverse mix of markets, with Jordan the largest Arab pharmaceutical exporter in the region and Lebanon almost entirely dependent on imports.
  • With the exceptions of Egypt and Israel, every country in the region is heavily dependent on imports.
  • According to the Jordanian Association of Pharmaceutical Manufacturers, 81 percent of its production is exported, 90 percent of which goes to other countries in the region.
  • Egypt is the largest market, followed by Saudi Arabia.
  • Other significant markets include Jordan, Lebanon, and the United Arab Emirates.
  • The total regional market is valued at over $12 billion and is expected to grow 10 to 15 percent annually, according to various estimates.
  • Smaller markets include countries such as Kuwait, estimated to be worth $365 million, and Oman, valued at $124 million.
  • Both rely largely on imported generics and branded drugs.
  • Israel spends 0.8 percent of GDP on healthcare, and local generics giant Teva Pharmaceutical Industries dominates its generics market.

Importance and scope of Pharma Industry

The pharmaceutical industry represents one of the most dynamic and demanding industries in the world. As health care continues to grow and account for a significant portion of the economy in the United States and throughout the world, the importance of the pharmaceutical and health care industry increases.

Over the years pharmacy has grown in the form of pharmaceuticals sciences through research and development processes. It is related to product as well as to services.

The various drugs 

 

Discovered and developed are its products and the healthcare it provides comes under the category of services

Pharmacy involves all the stages that are associated with the drugs i.e. discovery, development, action, safety, formulation, use, quality control, packaging, storage, marketing, etc. This profession has a large socio-economic relevance to the Indian economy. In India this sector is among the future economy drivers. It is committed to deliver high quality drugs and formulations at an affordable price, so that majority of people can afford them.

This profession has a large socio-economic relevance to the Indian economy. In India this sector is among the future economy drivers. It is committed to deliver high quality drugs and formulations at an affordable price, so that majority of people can afford them. The transformation of the sector from conventional pharmacy to drug experts, which is both desired and necessary to reach the global standards, has already made commendable progress

Liberalization, privatization and globalization (LPG) have helped the Indian pharmaceutical companies to achieve international recognition. It's remarkable to note that today several Indian pharma companies are approved by US FDA and are listed at NASDAQ.

 

The multibillion-dollar pharma industry grows mainly through knowledge wealth creation. This sector has transformed a lot over the years. The big pharma companies that were there about 15-20 years back are not in picture these days. 





Past Conference Report

Pharma Middle East 2016

Conference Series LLC successfully anchored its leading "12th Annual Pharma Middle East Congress" slated during September 25-27, 2017 at  Dubai, UAE.

Pharma Middle East 2017 is distinguished with the attendance of Editorial Board Members of supported Journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who made this conference rewarding and fecund.

Our 12th Annual Pharma Middle East Congress was based on the theme Pharmaceutical innovations: Much more than just medicine which has encrusted the below scientific sessions:

  • Pharmacological Sciences
  • Bio-Pharmaceutical Sciences
  • Pharmacognosy and Phytochemistry
  • Pharmaceutical Chemistry and Medicinal Chemistry
  • Nanotechnology
  • Drugs and Regulations
  • Industrial Pharmacy and Pharmacy Practice
  • Genetics, Genetic Engineering and Biomedical Engineering
  • Ethics in Pharmacy
  • Pre formulation Study &Techniques
  • Clinical Pharmacy and Pharmacotherapeutics
  • Green Chemistry in Pharmaceutical Industry
  • Pharmaceutical Microbiology and Biotechnology
  • Pharmaceutical Business and Market
  • Entrepreneurs Investment Meet

The conference received salutations by the honorable guests Randall J Bjork, Lotus Health, USA; Novotny L, Kuwait University, Kuwait and P G Shrotriya, NMIMS University, India.

Immense support was extended by the keynote lectures mentioned below:

  • Randall J Bjork, Lotus Health, USA
  • Farida Dabouz, FB2D Clinical Research Consulting Inc., Canada
  • Maria Lindau, Stockholm University, Sweden
  • Dong-Kwon Rhee, Sungkyunkwan University, South Korea
  • P G Shrotriya, NMIMS University, India

We specially thank Randall J Bjork, Lotus Health, USA and Farida Dabouz, FB2D Clinical Research Consulting Inc., Canada for their support as moderators for the conference and for their continous support for success of the conference.

Conference Series LLC wishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honourable guests, Valuable speakers, Poster presenters, students, delegates and special thanks to the Media Partners (The Pharma Review, Medical News Today, PMR, Medarabia, Research Asia Research News, Pharma Focus Asia and Pharmaceutical Tech.com) for their promotion to make this event a huge success.

With the enormous feedback from the participants and supporters of 6th Asia-Pacific Pharma Congress, Conference Series LLC is glad to announce "12th Annual Pharma Middle East Congress” slated during Sept 25-27, 2017 at Dubai, UAE.

2017 Highlights:

  • 300+ Participation (70% Industry and 30% Academia)
  • 7+ Keynote Speakers
  • 50+ Plenary Speakers
  • 20+ Exhibitors
  • 13 Innovative Educational Sessions
  • 5+ Workshops
  • B2B Meetings

 For more details, please visit: http://middleeast.pharmaceuticalconferences.com/


Past Reports  Gallery  



Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date Sep 25-27, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Media Partners

Conferenceseries Destinations